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Smacmimeticcompounds(SMCs)areexperimentalsmallmoleculesthatinducetumour necrosisfactoralpha(TNFa)-dependent
cancer celldeathby targeting the inhibitor ofapoptosisproteins.However, manycancer cell lines are resistant toSMC-mediated
apoptosis despitethe presence of TNFa. To add insight into the mechanism of SMC-resistance, we used functional siRNA-based
kinomic and focused chemical screens and identiﬁed suppressor of morphogenesis in genitalia-1 (SMG1) and NF-jB-inducing
kinase (NIK) as novel protective factors. Both SMG1 and NIK prevent SMC-mediated apoptosis likely by maintaining FLICE
inhibitory protein (c-FLIP) levels to suppress caspase-8 activation. In SMC-resistant cells, the accumulation of NIK upon SMC
treatment enhanced the activity of both the classical and alternative nuclear factor-jB pathways, and increased c-FLIP mRNA
levels.Inparallel,persistentSMG1expressioninSMC-resistantcellsrepressedSMC-mediatedTNFa-inducedJNKactivationand
c-FLIPlevelsweresustained.Importantly,SMC-resistanceisovercomebydepletingNIKandSMG1,whichappeartofacilitatethe
downregulationofc-FLIPinresponsetoSMCandTNFatreatment,leadingtocaspase-8-dependentapoptosis.Collectively,these
data show that SMG1 and NIK function as critical repressors of SMC-mediated apoptosis by potentially converging on the
regulation of c-FLIP metabolism.
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The inhibitor of apoptosis (IAP) proteins are key repressors of
programmed cell death. Evasion from apoptosis is a hallmark
oftumourigenesis,
1andconsequently,the IAPs havebecome
important targets for the development of anticancer thera-
pies.
2Currentapproachesthatareunderclinicaldevelopment
for the targeting of the IAPs include antisense oligonucleo-
tides that repress IAP gene expression and synthetic small
molecules that antagonize IAP function.
3
The suppression of apoptosis by the IAPs is primarily
mediated through the inhibition of caspase activity, either
directly via their baculoviral IAP repeat (BIR) domains or
indirectly through their ubiquitin E3 ligase RING domain. The
ability of the BIR2 domain of X-linked IAP (XIAP) to bind
and inhibit the effector caspases-3 and -7, and the ability of
the BIR3 domain of XIAP to function as a direct inhibitor for
theinitiatorcaspase-9,havebeenextensivelydocumented.
4,5
As well, recent evidence indicates that the ubiquitin E3 ligase
RING domain of cellular IAP1 (cIAP1) and cellular IAP2
(cIAP2) can indirectly inhibit apoptosis by modulating the
ubiquitination status of the kinase receptor-interacting protein
1 (RIP1).
6–8 In response to tumour necrosis factor alpha
(TNFa), cIAP1 or cIAP2 facilitates the ubiquitination of RIP1
and thereby blocks the recruitment of caspase-8 and FADD to
RIP1, preventing the formation of the death-inducing
complex II.
9,10 The indirect inhibition of caspase-8 by cIAP1
and cIAP2 is indispensable for the prevention of TNFa-
mediated apoptosis.
Smac mimetic compounds (SMCs) are small molecule
therapeutics that target the IAPs and are currently in clinical
trials for cancer.
3 The structure of SMCs were rationally
designed from a conserved IAP-binding motif that contains
the AVPI tetrapeptide amino terminal sequence of Smac,
which binds to the BIR2 and BIR3 domains of cIAP1, cIAP2
and XIAP.
11–13 The mode of action for SMCs in sensitive
cancer cells involves the rapid activation of the ubiquitin E3
ligase of cIAP1 and cIAP2, leading to autoubiquitination and
proteasomal degradation of these cIAPs.
6,14–17 In the
absence of the cIAPs, RIP1 ubiquitination is markedly
reduced,
6–8 thereby sensitizing cancer cells to TNFa-
mediated apoptosis via the preferential formation of the
death-inducing complex II.
Resistance to SMC treatment has been shown in diverse
cancer cell lines
9,18 and in a xenograft model.
18 The
concomitant treatment of SMC and TNFa can reverse the
resistance in some cancer cell lines to SMC treatment alone;
however, about half of the cell lines surveyed remain resistant
to SMC treatment despite the addition of exogenous TNFa.
9
This resistance may limit the impact of SMCs in the
clinic despite the abundance of TNFa in the tumour
microenvironment.
19 Therefore, identifying the basis for
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www.nature.com/cddisSMC-resistance will beneﬁt the application of SMCs as a
cancer therapy by allowing for the rational development of
treatment strategies.
To gain insight into the mechanism of SMC-resistance in
cancer cells, we undertook functional siRNA-based kinomic
screensandidentiﬁedtargetsthatsensitizecancercellstothe
SMCs AEG40730 and SM-164. On the basis of resistance to
cell death in response to SMC and TNFa treatment,
9 we
selected the non-small cell lung carcinoma (NSCLC) cell line
H226 for the investigation of pro-survival kinases. Interest-
ingly, we identiﬁed NF-kB-inducing kinase (NIK) as a pro-
survival kinase. This pro-survival property differs from the
previously suggested role of NIK as a pro-death regulator
functioning to promote the production of TNFa.
16,17 Further-
more, a siRNA screen that simultaneously targeted NIK in
combination with the kinome revealed that the additional loss
of suppressor of morphogenesis in genitalia-1 (SMG1)
synergized with NIK knockdown to cause apoptosis upon
SMC and TNFa co-treatment. We further propose that SMG1
and NIK are regulators for the metabolism of FLICE inhibitory
protein (c-FLIP), a caspase-8 inhibitor. Our results show that
SMG1 and NIK act as important repressors of SMC-mediated
cell death possibly by sustaining the expression of c-FLIP.
Results
Functional siRNA kinome screens identiﬁed NIK and
SMG1 as protective factors for SMC-mediated TNFa-
induced cell death. To explore factors underlying the
resistance of cancer cells to SMC-mediated TNFa-induced
cell death, we performed a synthetic lethal screen in which
691 kinome targets were individually knocked down before
the co-treatment of SMC (AEG40730) and TNFa.T o
determine the effects of each knockdown on cell viability in
response to the drugs, we used Alamar Blue, which
measures the activity of the mitochondrial respiratory
chain.
20 We previously reported that the NSCLC H226 is a
SMC-resistant cell line that has an intact apoptotic pathway
and the resistance of H226 cells to SMC-mediated TNFa-
induced cell death is reversed by c-FLIP silencing.
9 The
dependency on c-FLIP allows us to assess the robustness of
the assay by comparing SMC and TNFa sensitivity of H226
cells treated with c-FLIP siRNA to non-targeting siRNA. The
assay offered a wide dynamic range and negligible data
variability, resulting in a Z-factor of 0.59 (Figure 1a),
indicating that the kinome screen is a suitable assay for
identifying bona ﬁde hits.
21 The efﬁciency of siRNA targeting
c-FLIP was conﬁrmed by immunoblotting (Figure 1b). The
siRNA kinomic library screen identiﬁed CKS2, AKT2, KHK,
IKBKB, SMG1 and PIM2 as potential protective factors in
SMC-mediated TNFa-induced cell death (Figure 1c).
Interestingly, the synthetic lethal kinomic screen also
identiﬁed MAP3K14, which encodes for the protein NIK, as
the strongest suppressor in the library (Figure 1c).
NIK has been hinted as a component for the execution of
SMC-mediated cell death,
16,17 but here, we identify NIK as a
repressorofSMC-mediatedcelldeath.Thepotentialdualityof
NIK function to inhibit or promote SMC-mediated cell death
suggests that NIK function is dependent on the speciﬁc
cellular context. To investigate the contribution of additional
genes that might synergize with NIK-depletion in SMC-
mediated TNFa-induced cell death, we screened the kinomic
siRNA library with NIK-depleted H226 cells. We identiﬁed
NEK9, RPS6KA3, LYN, SMG1 and STK38L as genes that
potentially represent secondary blocks of SMC-mediated
TNFa-induced cell death in NIK-depleted H226 cells
(Figure 1d).
To determine which candidates from the NIK siRNA-
coupled secondary screen were most relevant in SMC-
mediated cell death, we assessed protein levels of the new
candidates in MDA-MB-231 cells in response to SMC
treatment. The MDA-MB-231 breast carcinoma cell line
responds robustly to SMC treatment (Figure 1e) in a manner
dependent on the production of TNFa,
16 with an IC50 of
1.32nM by SMC-AEG40730.
9 In the presence of SMC, we
found that NEK9, RPS6KA3, LYN, SMG1 and STK38L
maintained their protein expression levels, but SMG1 was
downregulated(Figure1f).ThelossofcIAP1,cIAP2andXIAP
by SMC treatment was also conﬁrmed (Figure 1f).
Since the loss of SMG1 coincides with the onset of SMC-
mediated cell death in MDA-MB-231 cells (Figures 1e and f),
we reasoned that SMG1 is likely to be a mechanistically
relevant protective factor against SMC treatment. We used
siRNAs from an alternative source to conﬁrm that the dual
silencing of SMG1 and NIK is more effective than single
SMG1 or NIK knockdown to sensitizing H226 cells to SMC-
mediated TNFa-induced cell death (Figure 2a). We next
extended our assessment to NSCLC H460 and H661, which
are among the most resistant cell lines to SMC treatment.
9
Similar to H226 cells, combined knockdown of NIK and SMG1
decreased viability of H460 and H661 cells that were treated
withSMCandTNFa(Figure2a).SMG1knockdownalonealso
sensitized H460 and H661 cells to SMC and TNFa treatment,
while the effect of NIK knockdown was more modest
(Figure 2a).
To assess the speciﬁcity of sensitization in SMG1 and NIK-
depleted cells, we analyzed the effect of SMG1 and NIK
knockdown with respect to cell death caused by other
apoptotic triggers, such as VP16, staurosporine and cyclo-
heximide in combination with TNFa. We found that combined
SMG1 and NIK knockdown has no effects on VP16- and
staurosporine-induced cell death, but sensitizes cell death
triggered by cycloheximide and TNFa treatment (Supplemen-
tary Figure 1). Sensitization of SMG1- and NIK-depleted cells
to cycloheximide and TNFa treatment may in part be due to
IAP downregulation by cycloheximide treatment.
22–24 Overall,
these results suggest that NIK and SMG1 are relatively speciﬁc
suppressors of SMC-mediated TNFa-induced cell death.
Depletion of SMG1 and NIK promotes SMC-mediated
TNFa-induced caspase-8 activation. To determine the
underlying mechanism of cell death in SMG1- and NIK-
depleted cells, we assessed for caspase activity in response
to SMC and TNFa treatment. As expected, treatment with
SMC resulted in the accumulation of NIK in all three cell lines
(Figure 2b and Supplementary Figure 2). In H226, H460 and
H661 cells treated with siRNA targeting combinations of NIK
and SMG1, we detected processing and activation of
caspase-3 and -8 following combined SMC and TNFa
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Cell Death and Diseasetreatment (Figure 2b and Supplementary Figure 2), in accord
with a role for caspases in SMC-mediated cell death. The
efﬁciency of siRNA-mediated SMG1 and NIK knockdown
was also conﬁrmed (Figure 2b and Supplementary Figure 2).
Next, we analyzed the effects of caspase-8 or -9 silencing
with siRNA in H226 cells that were depleted of SMG1 and NIK
before SMC and TNFa treatment. Downregulation of
caspase-8, but not caspase-9, prevented SMC-mediated
Figure 1 Functional siRNA kinome screens identiﬁed NIK and SMG1 as protective factors in SMC-mediated TNFa-induced cell death. (a) Evaluation and validation of
syntheticlethalsiRNAkinomescreen.siRNAtargetingc-FLIPandanon-targeting(NT) siRNAwereprintedto384-wellplatesina checkered pattern.H226 cellswerereverse
transfected for 24h and then treated with 100nM SMC-AEG40730 and 100ng/ml TNFa for an additional 48h. Cell viability was determined by Alamar Blue and plotted. The
solid horizontal lines show mean readings of the non-targeting and c-FLIP siRNAs. Broken lines represent three S.D. from the mean of each data set. The Z-factor was
calculated to be 0.59, demonstrating the robustness of the screen. (b) H226 cells were transfected with non-targeting siRNA or c-FLIP-siRNA. At 24h post-transfection, cells
wereharvestedandprotein expression levelsof c-FLIPwereanalyzedbywestern immunoblotting. b-actinwas usedasa loadingcontrol.(c)H226cellswere transfectedwith
siRNA library targeting the human kinome, non-targeting siRNA or c-FLIP-siRNA for 24h, and then exposed to SMC-AEG40730 and TNFa for 48h and cell viability was
determined by Alamar Blue. The percentage viability relative to siRNA transfection without drug exposure was plotted for the top hits. MAP3K14 (NIK) was identiﬁed as the
most potent repressor of cell death. (d) H226 cells were transfected with siRNA targeting NIK in combination with siRNA library targeting the human kinome for 24h.
Transfected cells were then exposed to SMC-AEG40730 and TNFa for an additional 48h and cell viability was determined. (e) MDA-MB-231 cells were treated with 100nM
SMC-AEG40730 and cell viability was determined at the indicated times. The percentage viability of MDA-MB-231 cells relative to vehicle ±S.E.M. from ﬁve independent
experimentswasplotted.*Po0.001signiﬁcantlydifferentfromvehicle,asdeterminedbyANOVAwithposthocTukey’sHSD.(f)MDA-MB-231cellsweretreatedwith100nM
SMC-AEG40730(SMC)for0–16h.CellswereharvestedandproteinsampleswereresolvedonSDS-PAGEandwesternimmunoblottedwiththeindicatedantibodies.b-Actin
was used as a loading control. Asterisk denotes a nonspeciﬁc band. The pro-survival kinase SMG1 identiﬁed in the synthetic lethal kinomic screen was downregulated in
SMC-sensitive MDA-MB-231 cells in response to IAP antagonism
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Cell Death and DiseaseTNFa-induced cell death in H226 cells depleted of SMG1 and
NIK (Figure 2c). RIP1 has been suggested to have an
important role in SMC-mediated cell death.
10,11 Accordingly,
we analyzed for the effect of RIP1 downregulation in cells that
were rendered sensitive to SMC-mediated TNFa-induced cell
death because of dual downregulation of SMG1 and NIK.
Similar to caspase-8 silencing, RIP1 knockdown protected
SMG1/NIK-depleted H226 cells from cell death triggered by
SMC and TNFa co-treatment (Figure 2c). The downregulation
of caspase-8, -9 and RIP1 by siRNA was conﬁrmed
(Figure 2d). These results indicate that caspase-8 and RIP1
are functional mediators of cell death triggered by SMC and
TNFa treatment.
The activation of caspases in SMG1- and NIK-depleted
cells in response to SMC and TNFa treatment indicates that
apoptosis might be the underlying mechanism of cell death.
We next measured apoptosis using ﬂow cytometry by
identifying the percentage of cells that are stained with
Figure 2 Depletion of SMG1 and NIK promotes SMC-mediated TNFa-induced caspase activation. (a) H226, H460 and H661 cells were transfected with siRNA targeting
SMG1 (red bars), NIK (blue bars), both (green bars) or non-targeting (NT) siRNA (black bars) as a control. At 24h after siRNA-mediated silencing, cells were exposed to
combinations of 100nM SMC-AEG40730 and100ng/ml TNFafor an additional48h. Cell viability was determined by Alamar Blue. Numbersrepresentthe average ±S.E.M.
of at least three assays. *Po0.01 signiﬁcantly different from non-targeting siRNA and vehicle, as determined by ANOVA with post hoc Tukey’s HSD. (b) H460 cells were
transfected with siRNA targeting SMG1, NIK, or non-targeting siRNA as a control. At 24h after siRNA-mediated silencing, cells were exposed to SMC for 1h before the
addition of 100ng/ml TNFa. At the indicated times of TNFa treatment, cells were harvested and subjected to western immunoblotting with antibodies recognizing caspase-8,
cleaved caspase-3, SMG1, NIK, cIAP1, cIAP2 and XIAP. b-Actin was used as a loading control. Processing of caspase-8 and -3 were detected in SMG1- and NIK-depleted
cellsfollowingcombinedSMCandTNFatreatment.(c)H226cellsweretransfectedwithsiRNAtargetingSMG1andNIK,incombinationwithsiRNAtargetingcaspase-8,-9or
RIP1 for 48h, and then exposed to SMC and TNFa for an additional 48h before cell viability was determined by Alamar Blue. Numbers represent the average ±S.E.M. of at
least three assays. *Po0.001 signiﬁcantly different from non-targeting siRNA and vehicle, as determined by ANOVA with post hoc Tukey’s HSD. (d) H226 cells were treated
with siRNA as in (c) for 48h, and isolated proteins were probed by western immunoblotting for the presence of caspase-8, -9 and RIP1. The silencing of caspase-8 or RIP1
prevented SMC-mediated TNFa-induced cell death in dually NIK- and SMG1-depleted cells
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Cell Death and Diseaseannexin V-ﬂuorescein isothiocyanate (FITC) without propi-
dium iodide uptake. Consistent with the activation of
caspases, we detected increased apoptosis in response to
SMC and TNFa treatment in H226, H460 and H661 cells
depleted of NIK and SMG1 (Figure 3 and Supplementary
Figure 3). Notably, the combined downregulation of NIK and
SMG1 resulted in a higher apoptotic index than single
knockdowns in response to SMC and TNFa treatment
(Figure 3 and Supplementary Figure 3). Together, these
results are consistent with the ability of SMCs to induce
caspase-8-mediated apoptosis upon TNFa treatment.
cIAP1, cIAP2 and XIAP cooperatively protect against
TNFa-induced cell death in cancer cells depleted of
SMG1 and NIK. The underlying mechanism of SMC-
mediated TNFa-induced cell death in cancer cells is
attributed to the ability of SMCs to antagonize the cIAPs
and possibly XIAP.
15,25,26.To deﬁne the contribution of each
of these IAPs in blocking TNFa-induced cell death, we
individually and jointly silenced cIAP1, cIAP2 and XIAP in
combination with SMG1 and NIK knockdown before TNFa
treatment. The combined silencing of SMG1 and NIK along
with the three IAPs was sufﬁcient to decrease H226, H460
and H661 cell viability, whereas the addition of TNFa
promoted more cell death in H226 cells (Figures 4a–c). We
further demonstrated the importance of IAP antagonism by
using SM-164, a different SMC that also potently targets the
IAPs.
15 As expected, SM-164 treatment similarly triggered
TNFa-mediated cell death in H226 cells depleted of SMG1
and NIK (Figure 4d). In accord with results from the kinomic
siRNA screens, the single knockdown of SMG1 or NIK also
sensitized these IAP-deﬁcient cancer cells to TNFa-mediated
cell death (Supplementary Figures 4A–I). Downregulation of
NIK was more potent at reducing cell viability than SMG1
silencing in IAP-deﬁcient H226 cells (Supplementary Figures
4B and C). Conversely, SMG1 knockdown was more
effective in promoting cell death than NIK downregulation
in IAP-deﬁcient H460 and H661 cells (Supplementary
Figures 4E, F, H and I). The efﬁciency of cIAP1, cIAP2 and
XIAP knockdown by siRNA was also conﬁrmed (Figure 4e
and Supplementary Figure 5). These results show that
targeting of these three IAPs is the most effective way
to induce cancer cell death in SMG1 and NIK-depleted
cancer cells.
Figure 3 Depletion of SMG1 and NIK allows cancer cells to undergo apoptosis in response to SMC and TNFa treatment. (a) H226 (b) H460 and (c) H661 cells were
transfectedwithsiRNAtargetingSMG1,NIKornon-targetingsiRNAasacontrol.At24haftersiRNA-mediatedsilencing,cellswereexposedtocombinationsof100nMSMC-
AEG40730 and 100ng/ml TNFa. At 24h after drug treatment, cells were stained with annexin V and propidium iodide to measure the rate of apoptosis by ﬂow cytometry.
Plotted numbers represent the average ±S.E.M. of three independent assays. *Po0.001 signiﬁcantly different from vehicle for the respective siRNA group treated with
vehicle, as determined by ANOVA with post hoc Tukey’s HSD. (d) Representative dot plots of H460 cells treated as in (b). The downregulation of SMG1 and NIK promoted
SMC-mediated TNFa-induced apoptosis in cancer cells
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Cell Death and DiseaseSMG1 blunts SMC-mediated TNFa-induced JNK activation
and c-FLIP turnover by the proteasome. Turnover of
c-FLIP is a determinant for SMC-induced cell death through
the extrinsic apoptosis pathway.
9 As SMG1 and NIK
silencing allows SMC-mediated TNFa-induced cell death to
proceed, we reasoned that SMG1 and NIK might affect c-FLIP
Figure 4 cIAP1,cIAP2 andXIAPcooperatively protectagainstTNFa-induced celldeathin cancercellsdepletedof SMG1andNIK.(a)H226,(b)H460 and(c)H661cells
were transfected with siRNA targeting cIAP1, cIAP2, XIAP, SMG1, NIK or non-targeting siRNA as a control. At 48h post-transfection, cells were treated with a vehicle (red
bars), or with 100ng/ml TNFa (blue bars) for an additional48h. (d) H226 cells were transfected with siRNA targeting SMG1,NIK or non-targetingsiRNA as a control for 24h,
and then treated with combinations of 100nM SM-164 and 100ng/ml TNFa for an additional 48h. Cell viability was determined by Alamar Blue. Numbers represent the
average ±S.E.M. of at least three assays. *Po0.01 signiﬁcantly different from non-targeting siRNA and vehicle, as determined by ANOVA with post hoc Tukey’s HSD.
(e) H226,H460 and H661cells weretransfectedwith siRNA targetingcIAP1,cIAP2and XIAP.At 48h post-transfection, cellswere harvestedand protein expression levels of
cIAP1, cIAP2 and XIAP analyzed by western immunoblotting. b-Actin was used as a loading control
Figure5 SMG1bluntsSMC-mediatedTNFa-inducedJNKactivationandc-FLIPturnoverbytheproteasome.(a)H226,H460andH661cellsweretransfectedwithsiRNA
targeting SMG1, NIK or non-targeting siRNA as a control for 24h, and then exposed to combinations of 100nM SMC-AEG40730 and 100ng/ml TNFa for 24h. Cells were
subsequently harvested and the protein expression levels of c-FLIP, SMG1 and NIK were determined by western immunoblotting. Asterisk denotes a nonspeciﬁc band.
(b) H460 and H661 cells were transfected with siRNA targeting SMG1, NIK or non-targeting siRNA as a control. At 24h post-transfection, cells were ﬁrst exposed to 100nM
SMC-AEG40730 for 1h, then treated with 100ng/ml TNFa in combination with vehicle, 20mM Gliotoxin, 20mM MG132 or 2mM MG262 for an additional 4h. Cells were
harvested and c-FLIP, SMG1 and NIK protein levels were determined. b-Actin was used as a loading control. Inhibition of the proteasome prevented SMC-mediated TNFa-
induced c-FLIP turnover. (c) MDA-MB-231 cells were treated with 100nM SMC-AEG40730 (SMC) for 0–16h. Cells were harvested, protein samples were resolved on SDS-
PAGEandwestern immunoblottedwith antibodiesagainstc-FLIP,phospho-JNKandtotalJNK.(d) H460andH661cellsweretransfectedwith siRNAtargetingSMG1,NIKor
non-targeting siRNA as a control for 24h, and then exposed to 100nM SMC-AEG40730 for 1h before the addition of 100ng/ml TNFa for the indicatedtimes. Harvestedcells
were processed for protein and analyzed for JNK activation by western immunoblotting. SMG1 knockdown enhances TNFa-mediated JNK activation in SMC-treated cells
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Cell Death and Diseaselevels in response to SMC and TNFa treatment. We found that
in SMG1- and NIK-depleted cells, c-FLIP levels decreased in
response to the combined treatment of SMC and TNFa
(Figure 5a). To determine the process that regulates c-FLIP
metabolism, we next screened an inhibitor library that covers a
wide spectrum of proteases (Supplementary Table 1). We
identiﬁed proteasome inhibitors gliotoxin and MG132 as the
most potent blockers of c-FLIP downregulation in dually
Smac mimetic compound mode of action
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Cell Death and DiseaseSMG1- and NIK-depleted H460 and H661 cells treated with
SMC and TNFa (Figure 5b and Supplementary Figure 6). In
addition, the proteasome inhibitor MG262 similarly prevented
c-FLIP degradation (Figure 5b). These results indicate that the
proteasome has a major role in SMC-mediated c-FLIP
turnover triggered by TNFa.
JNK-mediated activation of the ubiquitin–proteasome
pathway can facilitate the downregulation of c-FLIP.
27
We have previously shown that in cancer cell lines
resistant to SMC treatment, JNK activation is repressed in
response to TNFa.
9 In contrast, SMC treatment activates the
JNK pathway in MDA-MB-231 cells, a SMC-sensitive cell line
(Figure 5c). We therefore examined for the activation of JNK
in response to SMC and TNFa treatment in SMG1- and NIK-
depleted cells. In H460 and H661 cells treated with SMC,
silencing of SMG1, but not NIK, led to increased TNFa-
mediated activation of JNK1, JNK2 and JNK3 (Figure 5d).
Together, these data suggest that SMG1 represses JNK
activityandpreventsc-FLIPdegradationbytheproteasomein
response to SMC and TNFa treatment.
Upregulation of NIK by SMC treatment activates both the
classical and alternative NF-jB pathways and enhanced
c-FLIP transcription. As NIK did not regulate c-FLIP levels
via the JNK pathway, we next investigated the possibility that
NIK, as a modulator of nuclear factor-kB (NF-kB) pathway,
might regulate c-FLIP transcription. Activation of alternative
NF-kB pathway requires the processing of phosphorylated-
p100 to produce p52.
28 Phosphorylation of p100 can be either
directly catalyzed by NIK or indirectly via IKKa dimers.
28
Furthermore, activated NIK can cross-talk with the classical NF-
kB pathway through the NIK-IKK complex.
29 In response to
SMC treatment, NIK protein levels accumulated in H226, H460
and H661 cells (Figure 2B and Supplementary Figure 2),
thereby promoting the production of p52 (Figures 6a and c). As
expected, when NIK was silenced by siRNA, production of p52
decreased in response to SMC treatment (Figures 6a and c).
Downregulation of SMG1 showed no effect on either NIK levels
or p52 production (Figures 2b, 6a and c, Supplementary
Figure 2). Moreover, SMC treatment promoted persistent
phosphorylation of p65, indicating that the classical NF-kB
pathway was also activated (Figure 6c). Silencing of NIK, but
not SMG1, repressed SMC-mediated phosphorylation of p65
(Figure 6c). As the increase in NF-kB activity may modulate
c-FLIP transcription,
30 we next assessed for c-FLIP mRNA
levels after SMC and TNFa treatment. In H226 cells, c-FLIP
mRNA levels markedly increased in response to SMC and
TNFa treatment (Figure 6b). Knockdown of NIK, but not SMG1,
blocked the increase in c-FLIP mRNA levels (Figure 6b).
Similarly, NIK knockdown reduced c-FLIP messages in H460
and H661 cells treated with SMC and TNFa (Supplementary
Figure 7). Therefore, these results indicate that NIK
upregulation by SMC treatment activates both the classical
and alternative NF-kB pathways and may maintain c-FLIP
levels by enhancing the amount of c-FLIP transcripts.
Downregulation of IAPs and c-FLIP leads to cancer cell
death. Silencing of endogenous SMG1 and NIK sensitizes
cancer cells to SMC-mediated TNFa-induced cell death
(Figures 1–3 and Supplementary Figure 3). Similarly, siRNA-
mediated downregulation of SMG1 and NIK in combination
with IAP silencing also promoted cell death (Figure 4 and
Supplementary Figure 4). The ability of SMG1 and NIK to
maintain TNFa-regulated c-FLIP levels in response to SMC
Figure 6 SMC treatment activates both the classical and alternative NF-kB
pathways via NIK, promoting c-FLIP transcription. (a) H226 cells were transfected
with siRNA targeting SMG1, NIK or non-targeting siRNA as a control for 24h, and
then exposed to combinations of 100nM SMC-AEG40730 and 100ng/ml TNFa for
an additional 24h. Cells were harvested and subjected to western immunoblotting
with antibodies recognizing p100 and p52. b-Actin was used as a loading control.
(b) H226 cells treated as in (a) were harvested and RNA was isolated for real-time
qRT-PCR to determine c-FLIP mRNA levels. Fold changes from four independent
experiments relative to non-targeting siRNA and vehicle ±S.E.M. normalized
against GAPDH mRNA levels were plotted; siRNA targeting SMG1: red bars; NIK:
blue bars; both: green bars; non-targeting siRNA: black bars. Numbers represent
theaverage±S.E.M.ofatleastthreeassays.*Po0.001signiﬁcantlydifferentfrom
non-targeting siRNA and vehicle, as determined by ANOVA with post hoc Tukey’s
HSD. (c) H226, H460 and H460 cells were transfected with siRNA targeting SMG1,
NIKornon-targetingsiRNAasacontrol.At24hpost-transfection,cellsweretreated
with 100nM SMC-AEG40730 for an additional 24h. Cells were then harvested and
subjected to western immunoblotting with antibodies recognizing p100, p52,
phospho-p65andp65.DownregulationofNIKblocksSMC-inducedactivationofthe
classical and alternative NF-kB pathways, as well as SMC- and TNFa-mediated
induction of c-FLIP transcripts
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Cell Death and Diseasetreatment (Figures 5 and 6) suggests that the IAPs and
c-FLIP act in concert to protect cells from TNFa-initiated
death signals. Accordingly, we sought to determine the
individual and combined contribution of cIAP1, cIAP2, XIAP
and c-FLIP on TNFa-mediated cell death. In H226 cells,
combined downregulation of c-FLIP, cIAP1 and XIAP
markedly decreased cell viability that was further sensitized
by the addition of TNFa (Figure 7a). In H460 and H661 cells,
downregulation of any one of the three IAPs along with
c-FLIP promoted cell death and the effects were the most
pronounced with the dual knockdown of XIAP and c-FLIP
(Figures 7b and c). Remarkably, the knockdown of XIAP and
c-FLIP in H460 cells induced signiﬁcant cell death
(Figure 7b). Together, these results show that endogenous
IAPs and c-FLIP are crucial in maintaining cancer cell
viability.
Discussion
SMG1 and NIK are novel repressors of SMC-mediated
TNFa-induced apoptosis. SMCs are rationally designed
small molecules for cancer therapies that target the
IAPs. The ability of SMCs to induce TNFa-dependent cell
death depends on the molecular signature of the cancer
cell.
9 Although the basic components necessary for the
execution of cell death by SMCs are relatively well-deﬁned,
the underlying molecular pathways involved in SMC-
resistance in the presence of exogenous TNFa remain
poorly understood. Here, we utilized a functional siRNA
kinomic screen to identify factors involved in SMC-
resistance. We show that the protein kinases NIK and
SMG1 have important roles in protecting cancer cells from
SMC-mediated TNFa-induced apoptosis, likely through
sustaining expression levels of c-FLIP that corresponds to
the long isoform.
31 Speciﬁcally, SMG1 may maintain c-FLIP
levels by repressing JNK activation that consequently
prevents proteasomal degradation of c-FLIP, whereas NIK
may maintain transcriptional levels of c-FLIP mRNA by
activating both the classical and alternative NF-kB pathways
(Figure 8).
The dual role of NIK in SMC-mediated apoptosis. The
identiﬁcation of NIK as a protective factor in SMC-mediated
TNFa-induced apoptosis underscores the duality of the
NF-kB pathway. The loss of cIAP1 and cIAP2 by SMC
treatment allows for the accumulation of NIK,
16,17,32 a critical
Figure 7 DownregulationofIAPsandc-FLIPleadstocancercelldeath.(a)H226,(b)H460and(c)H661cellsweretransfectedwith siRNAtargetingcIAP1,cIAP2,XIAP,
c-FLIP or non-targeting siRNA as a control. At 48h post-transfection, cells were exposed to 100ng/ml TNFa for an additional 48h before subjected to a cell viability assay.
Numbers represent the average ±S.E.M. of at least four assays. *Po0.001 signiﬁcantly different from non-targeting siRNA samples treated with vehicle, as determined by
ANOVA with post hoc Tukey’s HSD
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Cell Death and Diseaseregulator that activates the alternative NF-kB pathway, but
also cross-talks to activate the classical NF-kB pathway.
29 In
SMC-sensitive cell lines, activation of the NF-kB pathways
upregulates TNFa levels,
16,17 which acts in an autocrine
manner to facilitate SMC-mediated apoptosis.
18 By
comparison, our current ﬁndings show that in SMC-
resistant cell lines, NIK is pro-survival and can activate
NF-kB pathways that may sustain c-FLIP expression. The
consequence of persistent c-FLIP expression is the
suppression of apoptosis, as c-FLIP inhibits caspase-8 to
block the progression of cell death.
33,34 Hence, the role for
NIK in SMC-mediated cell death reﬂects the reliance of
cancer cells on both NF-kB pathways for the balance
between survival and death.
SMG1 and c-FLIP are potential biomarkers for SMC
responsiveness. Our studies also identiﬁed SMG1 as
another repressor of SMC-mediated TNFa-induced
apoptosis. SMG1 has been previously linked to diverse
cellular responses including oxidative stress, hypoxia, TNFa-
mediated signalling, and mRNA surveillance mechanisms
regulating nonsense-mediated mRNA decay.
35–38 We
propose that a connection exists between SMG1 and
c-FLIP turnover through the JNK signalling pathway.
Notably, we previously reported that in SMC-resistant cells,
TNFa-mediated activation of JNK is repressed following SMC
treatment.
9 In contrast, knockdown of SMG1 in SMC-
resistant cells allows downstream JNK signalling to
proceed. Activated JNK can in turn phosphorylate ITCH, an
ubiquitin E3 ligase that has been linked to facilitate c-FLIP
turnover in a proteasome-dependent manner,
27,39 a property
that is consistent with our observation that c-FLIP meta-
bolism is blocked by proteasome inhibitors. Furthermore, we
found that SMC-induced loss of SMG1 in SMC-sensitive
MDA-MB-231 cells is correlated with prolonged JNK
activation and c-FLIP downregulation. Given these
observations, we propose that the downregulation of SMG1
and c-FLIP might serve as functional biomarkers for SMC
responsiveness.
Targeting IAPs and c-FLIP: implications for cancer
therapy. Our results raise the prospect of addressing the
potential obstacles faced with IAP-targeting strategies in
cancer therapies. Notably, the combined knockdown of XIAP
and c-FLIP was sufﬁcient to cause marked cell death in
NSCLC H460 and H661, even in the absence of exogenous
TNFa, suggesting a heightened reliance on XIAP and c-FLIP
for survival in certain cancer cells.
40 Moreover, SMC-induced
apoptosis and MDA-MB-231 xenograft tumour regression
were found to be the most effective when SMCs potently
target cIAP1, cIAP2 and XIAP concurrently.
15 Overall, these
results imply that the combination of a pan-IAP SMC and
c-FLIP silencing would maximize cancer cell death.
The deciphering of SMC modeof action will have signiﬁcant
implications on the applicability of SMCs as an emerging
cancer therapeutic. Our strategy demonstrates the power of
coupling functional siRNA and focused chemical screens with
a rational targeted approach to investigate the underlying
mechanism of biological processes. We have previously
established that the silencing of c-FLIP by siRNA reverses
SMC-resistance in a broad range of cancer cell lines to
extrinsic apoptosis triggers such as TNFa and TRAIL.
9 We
now show that NIK and SMG1 are potential regulators of
c-FLIP level at distinct points in SMC-resistant cancer cells.
These ﬁndings provide novel insight into the complex
mechanism of SMC-mediated apoptosis and identify NIK
and SMG1 as candidate therapeutic targets for SMC
sensitization.
Materials and Methods
Reagents. SMC AEG40730
6 was synthesized by Vibrant Pharma Inc.
(Brantford, ON, Canada). SMC SM-164 was kindly provided by
Dr. Shaomeng Wang (University of Michigan).
15 Protease inhibitor library (version
2.0), gliotoxin and MG-132 and TNFa were obtained from Enzo Life Sciences
(Farmingdale, NY, USA). MG-262, was obtained from Calbiochem (Gibbstown,
NJ, USA). VP16, staurosporine and cycloheximide were obtained from Sigma
(St. Louis, MO, USA).
Figure 8 Proposed schematic of the roles of NIK and SMG1 in sensitive versus
resistant cells in response to SMC and TNFa treatment. In SMC sensitive cells
(left side), removal of the cIAPs by SMC treatment prevents ubiquitination of
RIP1, allowing RIP1 to bind and activate the death complex II that includes caspase-8
andFADD (A). Degradationof SMG1 allowsfor theactivation of JNKin responseto
TNFa, leading to proteasomal downregulation of c-FLIP possibly through the ITCH-
mediated pathway (B). As c-FLIP is downregulated, caspase-8 activation is able to
proceed and apoptosis ensues. In SMC-resistant cells (right side), the level of
SMG1 persists in spite of SMC and TNFa treatment, blunting the activation of JNK
(C) and thereby preventing proteasomal degradation of c-FLIP. In addition,
depletion of cIAPs by SMC treatment allows NIK to accumulate, resulting in
activation of both the classical and alternative NF-kB pathways (D), which may
elevate transcriptional levels of c-FLIP. SMG1 and NIK functions appear to
converge by sustaining the protein expression level of c-FLIP, thereby preventing
caspase-8 activation and repressing SMC-mediated apoptosis. Silencing of both
SMG1 and NIK converts SMC-resistant cells to becomesensitive to SMC treatment
in response to TNFa
Smac mimetic compound mode of action
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Cell Death and DiseaseCell culture. MDA-MB-231 breast carcinoma, NCI-H226 (H226), NCI-H460
(H460)andNCI-H661(H661)cellswereobtainedfromATCC(Manassas,VA,USA)
and maintained at 371C and 5% CO2 in DMEM media supplemented with 10%
heat-inactivated fetal calf serum, penicillin, streptomycin and 1% non-essential
amino acids (all from Invitrogen, Burlington, ON, Canada).
Functional siRNA-based synthetic lethal screen validation. For
the development of a functional siRNA-based synthetic lethal screen that would
identifyprotectivefactorsagainstSMCtreatment,H226cellswereselectedbecause
of their strong resistance toward SMC-mediated TNFa-induced cell death.
9.siRNA
targeting c-FLIP was used as a positive control as c-FLIP has been previously
identiﬁed as a protective factor against SMC treatment.
9 siRNA targeting c-FLIP
(DharmaconON-TARGETplusSMARTpool,Lafayette,CO,USA)andnon-targeting
siRNA (Dharmacon Accell) were printed to 384-well plates in a checkered pattern.
H226 cells were reversed transfected with 10nM siRNA using DharmaFECT I
(Dharmacon) for 24h, followed by treatment of 100nM SMC-AEG40730 and
100ng/ml TNFa for an additional 48h. Cell viability was determined by resazurin/
Alamar Blue vital dye (Sigma-Aldrich) that measures mitochondrial metabolic
activity.
20 Theresults wereanalyzedto determine thetwoextremes ofactivityrange
and robustness of the screening assay. The screening window coefﬁcient, or
Z-factor, was determined as followed:
21
Z ¼ 1  
ð3sFLIP þ 3sNTÞ
jmFLIP   mNTj
A Z-factor 40.5 represented an excellent assay suitable for high-throughput
screening.
Kinome siRNA screening. A human kinome library containing 691 siRNAs
targetinggenes that encodefor protein kinases, lipid kinases, carbohydrate kinases
and regulatory subunits was obtained from Qiagen (Mississauga, ON, Canada).
Each siRNA duplex from the kinome library was printed to 384-well plates that also
contained designated wells with siRNA targeting c-FLIP or non-targeting siRNA.
H226 cells were reversed transfected with 10nM siRNA using DharmaFECT I. At
24h post-transfection, cells in paired plates were treated with either vehicle or
100nM SMC-AEG40730 and 100ng/ml TNFa. At 48h post-drug exposure, cell
viability was assessed by Alamar Blue, and the percentage viability was calculated
as the ratio of siRNA treatment in the presenceof drugs to vehicletreatment. Singly
synthetic lethal siRNAs (o50% viability) were excluded from further analysis. For
the NIK–siRNA-coupled screen, cells were transfected with 2nM siRNA targeting
NIK in addition to the individual genes in the library. At 24h post-transfection, cells
weretreated with SMC-AEG40730 and TNFa for an additional48h and cell viability
was determined.
Additional siRNAs targeting SMG1, NIK, cIAP1, cIAP2, XIAP, caspase-8, -9 and
RIP1 were obtained from Dharmacon (ON-TARGETplus SMARTpool). A non-
targetingpoolsiRNAcontrol(Dharmacon)was usedasan RNAinterferencecontrol
for all siRNA transfections.
Western immunoblotting. Cells were collected by centrifugation and lysed
in 50mM Tris-HCl, pH 8.0. containing 1% Triton X-100, 150mM NaCl, 1mM NaF,
0.1mM phenylmethylsulfonyl ﬂuoride, 5mg/ml pepstatin A and 10mg/ml each of
leupeptin and aprotinin (lysis buffer) and insoluble materials were pelleted by
centrifugation at 12000 g for 30min at 41C. Supernatants were collected for
protein determination by Bio-Rad (Mississauga, ON, Canada) Protein Assay using
bovine serum albumin as a standard. Samples were solubilized with sample buffer
(62.5mM Tris-HCl, pH 6.8 containing 2% SDS, 1% b-mercaptoethanol and 5%
glycerol), and equal amounts of samples were separated on polyacrylamide gels
followed by transferred to nitrocellulose. Following protein transfer, individual
proteins were detected by western immunoblotting using the following antibodies
recognizing: b-actin (clone AC-15) from Sigma; cleaved caspase-3 (9661),
caspase-9 (9502), JNK (9252), phospho(T183/Y185)-JNK (9251), Lyn (clone 5G2),
NIK (4994), p100/p52 (4882), p65 (clone C22B4), phosphor(S536)-p65 (clone
93H1) and SMG1 (4993, 9592) from Cell Signaling Technology (Danvers, MA,
USA); caspase-8 (AHZ0502) from Invitrogen; c-FLIP (clone NF6) from Alexis
Biochemicals (Lausen, Switzerland); RPS6KA3 (TA303691) from Origene
(Rockville, MD, USA); NEK9 (ab71812) and STK38L (ab84873) from Abcam
(Cambridge, MA, USA); and RIP1 (clone 38) from BD Biosciences (Franklin Lakes,
NJ, USA). Our rabbit anti-rat IAP1 and IAP3 polyclonal antibodies were used to
detect cIAP1/2 and XIAP, respectively.
7 Bound primary antibodies were reacted
with secondary antibodies conjugated to AlexaFluor680 (Invitrogen) or IRDye800
(Rockland, Gilbertsville, PA, USA) and the infrared ﬂuorescent signals were
detected using the Odyssey Infrared Imaging System (LI-COR).
Apoptosis assay. siRNA-targeted and drug-treated cells were used to
determinethetranslocationofphosphatidylserinefromtheinnertotheoutersurface
oftheplasmamembraneduringapoptosisbyusingthehumanphospholipid-binding
protein, annexin V, conjugated to FITC, as according to the manufacturer’s
instructions (BD Biosciences). The percentage of apoptotic (annexin V-positive and
propidium iodide-negative) cells was determined by ﬂow cytometric analysis
(BD Biosciences Immunocytometry Systems BD FACSDiva and De Novo FCS
Express V3).
Quantitative reverse transcription-PCR. To measure relative mRNA
expression levels, total RNA was isolated from cells after siRNA and drug
treatments (RNeasy Mini Kit, Qiagen). One step quantitative reverse transcription-
PCR was performed using the QuantiTect SYBRGreen RT-PCR kit (Qiagen) with
100ng total RNA with validated gene-speciﬁc QuantiTect Primers (c-FLIP:
QT00064554; GAPDH: QT01192646; b-actin: QT01680476) on an Eppendorf
Mastercyclereprealplex.NogenomicDNAampliﬁcationwasseenwithcontrolsthat
lack the reverse transcription step (i.e., 410 cycle difference compared with
complete protocol).
Statistical analysis. Statistical comparisons were performed using ANOVA
with post hoc Tukey’s HSD.
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